Reducing morbidity and mortality in high risk patients with statins

References

• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the national cholesterol education program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• CannonCPIntensive versus moderate lipid lowering with statins after acute coronary syndromes (PROVE-IT Study)N Engl J Med20043501495150415007110
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative GroupMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trialLancet200236072212114036
   PubMed Web of Science ®Google Scholar
• GrundySMImplications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelinesCirculation200411022723915249516
   PubMed Web of Science ®Google Scholar
• WatersDDTreating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?Am J Cardiol20049315415814715339
   PubMed Web of Science ®Google Scholar
• DeedwaniaPReduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets studyLancet200636891992816962881
   PubMed Web of Science ®Google Scholar
• ShepherdJEffect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: The Treating to New Targets (TNT) studyDiabetes Care2006291220122616731999
   PubMed Web of Science ®Google Scholar
• KhushKEffect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets studyCirculation200711557658317261662
   PubMed Web of Science ®Google Scholar
• ShepherdJEffect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) studyClin J Am Soc Nephrol200721131113917942759
   PubMed Web of Science ®Google Scholar
• WingardDLClustering of heart disease risk factors in diabetic compared to nondiabetic adultsAm J Epidemiol198311719266823949
   PubMed Web of Science ®Google Scholar
• SternMPBody fat distribution and hyperinsulinemia as risk factors for diabetes and cardiovascular diseaseArteriosclerosis198661231303513749
   PubMedGoogle Scholar
• ReavenGMBanting lecture 1988. Role of insulin resistance in human diseaseDiabetes198837159516073056758
   PubMed Web of Science ®Google Scholar
• SattarNMetabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention StudyCirculation200310841441912860911
   PubMed Web of Science ®Google Scholar
• DeedwaniaPCMetabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease?Circulation20041092414707015
   PubMed Web of Science ®Google Scholar
• GirmanCJThe metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Am J Cardiol20049313614114715336
   PubMed Web of Science ®Google Scholar
• OiSLovastatin prevents angiotensin II–induced cardiac hypertrophy in cultured neonatal rat heart cellsEur J Pharmacol199937613914810440099
   PubMed Web of Science ®Google Scholar
• AlbertiKGThe metabolic syndrome – a new worldwide definitionLancet20053661059106216182882
   PubMed Web of Science ®Google Scholar
• British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke AssociationJBS 2: Joint British Societies’ guidelines on prevention of cardiovascular disease in clinical practiceHeart200591Suppl 5v1v5216365341
   PubMed Web of Science ®Google Scholar
• SmithSCJrAHA/ACC guidelines for secondary prevention for patients with coronary and other atheroscle-rotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood InstituteCirculation20061132363237216702489
   PubMed Web of Science ®Google Scholar
• GrundySMDiagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementCirculation20051122735275216157765
   PubMed Web of Science ®Google Scholar
• EckelRHPreventing cardiovascular disease and diabetes A call to action from the American Diabetes Association and the American Heart AssociationCirculation20061132943294616801475
   PubMed Web of Science ®Google Scholar
• BaigentCEfficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statinsLancet20053661267127816214597
   PubMed Web of Science ®Google Scholar
• KahnRThe metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care2005282289230416123508
   PubMed Web of Science ®Google Scholar
• ZhuSWaist circumference and obesity-associated risk factors among whites in the third National Health and Nutrition Examination Survey: clinical action thresholdsAm J Clin Nutr20027674374912324286
   PubMed Web of Science ®Google Scholar
• FordESIncreasing prevalence of the metabolic syndrome among US adultsDiabetes Care2004272444244915451914
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study GroupRandomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)Lancet1994344138313897968073
   PubMed Web of Science ®Google Scholar
• LaRosaJCIntensive lipid lowering with atorvastatin in patients with stable coronary diseaseN Engl J Med3521425143515755765
   PubMed Web of Science ®Google Scholar
• AlmdalTThe independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population based study of 13,000 men and women with 20 years of follow-upArch Intern Med20041641422142615249351
   PubMed Web of Science ®Google Scholar
• StamlerJDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care1993164344448432214
   PubMed Web of Science ®Google Scholar
• HaffnerSMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med19983392292349673301
   PubMed Web of Science ®Google Scholar
• HaffnerSMMortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarctionN Engl J Med19983392292349673301
   PubMed Web of Science ®Google Scholar
• PyoralaKCholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S)Diabetes Care206146209096989
   PubMed Web of Science ®Google Scholar
• KeechASecondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trialDiabetes Care2003262713272114514569
   PubMed Web of Science ®Google Scholar
• American Diabetes Association: Standards of medical care in diabetes (Position Statement)Diabetes Care200528Suppl 1S4S3615618112
   PubMedGoogle Scholar
• KorenMJClinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE studyJ Am Coll Cardiol2004441772177915519006
   PubMed Web of Science ®Google Scholar
• TreasureCBBeneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery diseaseN Engl J Med19953324814877830728
   PubMed Web of Science ®Google Scholar
• LaufsUUpregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitorsCirculation199897112911359537338
   PubMed Web of Science ®Google Scholar
• VaughanCJStatins do more than just lower cholesterolLancet1996348107910828874463
   PubMed Web of Science ®Google Scholar
• KrumHStatins and chronic heart failure: do we need a large-scale outcome trial?J Am Coll Cardiol2002391567157312020481
   PubMed Web of Science ®Google Scholar
• HorwichTBLow serum total cholesterol is associated with marked increase in mortality in advanced heart failureJ Card Fail2002821622412397569
   PubMed Web of Science ®Google Scholar
• MortensenSADose-related decrease of serum coenzyme Q10 during treatment with HMG-CoA reductase inhibitorsMol Aspects Med199718SupplS137S1449266515
   PubMedGoogle Scholar
• KjekshusJA statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristicsEur J Heart Fail200571059106916227145
   PubMed Web of Science ®Google Scholar
• TavazziLRationale and design of the GISSI heart failure trial: a large trial to assess the effects of n-3 polyunsaturated fatty acids and rosuvastatin in symptomatic congestive heart failureEur J Heart Fail2004663564115302013
   PubMed Web of Science ®Google Scholar
• CoreshJPrevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination SurveyAm J Kidney Dis20034111212500213
   PubMed Web of Science ®Google Scholar
• GoASChronic kidney disease and the risks of death, cardiovascular events, and hospitalizationN Engl J Med20043511296130515385656
   PubMed Web of Science ®Google Scholar
• FriedLFEffect of lipid reduction on the progression of renal disease: a meta-analysisKidney Int20015926026911135079
   PubMed Web of Science ®Google Scholar
• CollinsRMRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo controlled trialLancet20033612005201612814710
   PubMed Web of Science ®Google Scholar
• KorenMJALLIANCE InvestigatorsFocused atorvastatin therapy in managed-care patients with coronary heart disease and CKDAm J Kidney Dis20095374175019216014
   PubMed Web of Science ®Google Scholar
• SeverPSPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• ColhounHMPrimary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancet200436468569615325833
   PubMed Web of Science ®Google Scholar
• SeverPSPrevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trialLancet20033611149115812686036
   PubMed Web of Science ®Google Scholar
• Stroke Prevention by Aggressive Reduction in Cholestrol Levels (SPARCL) InvestigatorsKaramJGHigh-dose atorvastatin after stroke or transient ischemic attackJ Cardiometab Syndr20083686918326981
   PubMedGoogle Scholar
• NissenS(REVERSAL) A prospective, randomized, double blind, multi-center study comparing the effects of atorvastatin vs pravastatin on the progression of coronary atherosclerotic lesions as measured by intravascular ultrasoundAmerican Heart Association Scientific Sessions 2003November 9–12, 2003Orlando, FloridaPlenary Session XI: Late Breaking Clinical Trials.
   Google Scholar
• NissenSEfor the ASTEROID InvestigatorsEffect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trialJAMA20062951556156516533939
   PubMed Web of Science ®Google Scholar
• PasceriVRandomized Trial of Atorvastatin for Reduction of Myocardial Damage during Angioplasty/Coronary Intervention (ARMYDA) TrialCirculation200411067467815277322
   PubMed Web of Science ®Google Scholar
• PattiGAtorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trialJ Am Coll Cardiol2007491272127817394957
   PubMed Web of Science ®Google Scholar
• HerrmannJPreprocedural statin medication reduces the extent of periprocedural non-Q-wave myocardial infarctionCirculation2002106172180218312390944
   PubMed Web of Science ®Google Scholar